Among patients with muscle-invasive bladder cancer, dose-dense MVAC significantly improved the 3-year rate of PFS and time to progression vs gemcitabine plus cisplatin in the neoadjuvant setting.
In a head-to-head trial in patients with previously treated HER2-positive metastatic breast cancer, trastuzumab deruxtecan reduced risk of disease progression or death by 72% compared with trastuzumab emtansine, a current standard of care.
In this combined analysis from the ongoing STAMPEDE platform trial, 2 years of abiraterone acetate plus prednisolone added to ADT was associated with a significant improvement in metastasis-free survival and OS in patients with high-risk nonmetastatic prostate cancer.
In this randomized, phase III trial, the addition of abiraterone to ADT plus docetaxel was associated with a significant improvement in rPFS and overall survival in men with de novo metastatic CSPC.
With additional follow-up, nivolumab + CT continued to show an OS benefit over CT alone in previously untreated patients with advanced gastroesophageal cancers.
[vic]-Trastuzumab duocarmazine, a novel antibody–drug conjugate, improved median PFS vs physician’s choice therapy in pretreated HER2+ locally advanced or metastatic breast cancer.
Addition of pembrolizumab to chemotherapy improved both OS and PFS in patients with locally recurrent unresectable or metastatic triple-negative breast cancer with PD-L1 CPS ≥10.
In patients with colorectal cancer and unresectable liver metastases, the addition of transarterial radioembolization with yttrium-90 to second-line chemotherapy demonstrated significant improvements in PFS and hepatic PFS with a higher rate of grade ≥3 toxicity.
Phase Ib results suggest cabozantinib plus atezolizumab may be active in mCRPC patients with visceral or extrapelvic lymph node metastases.
In this single-arm study in patients with previously treated HER2-mutated NSCLC, trastuzumab deruxtecan demonstrated robust antitumor activity with a safety profile consistent with previous reports.
In this phase I study subset analysis, datopotamab deruxtecan demonstrated antitumor activity and manageable toxicity in patients with heavily pretreated advanced NSCLC with actionable genomic alterations.
In this single-arm phase II trial, second-line therapy with trastuzumab deruxtecan showed a response rate of 38% and durable responses following a trastuzumab-containing regimen in Western patients with HER2+ advanced gastric or GEJ cancer with no unexpected adverse events.
After a median follow-up of more than 3 years, this update showed sustained overall survival benefit with adding durvalumab to etoposide/platinum chemotherapy for the first-line treatment of patients with extensive-stage SCLC.
In this final analysis of the landmark COSMIC-311 trial, cabozantinib maintained a significant PFS benefit vs placebo in patients with radioiodine-refractory/-ineligible differentiated thyroid cancer after prior VEGFR TKI therapy.
In patients with previously treated mCRPC, the addition of 177Lu-PSMA-617 to standard of care resulted in improvements in health-related quality of life and time to worsening of pain and first symptomatic skeletal events, in addition to the previously reported OS and rPFS benefits.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.